The first phase of the clinical trial of the Iranian COVID-19 vaccine, dubbed Fakhra, was completed, said the manager of the project to develop the vaccine.
In an address to a ceremony to mark the first phase’s completion, Ahmad Karimi said following the collection and final analysis of the data, the second phase will begin, IRNA reported.
Being developed by the Iranian Defense Ministry, the jab has been named after the former head of the ministry’s Organization of Defensive Innovation and Research Mohsen Fakhrizadeh, who was assassinated near Tehran in November 2020 in an act of terror, according to Press TV.
The first phase of the vaccine’s human trial kicked off in March in a ceremony attended by Defense Minister Brigadier General Amir Hatami and Health Minister Saeed Namaki. The first volunteer was Martyr Fakhrizadeh’s son.
Karimi noted that the protocols pertaining to the second phase have been presented to the Health Ministry, expressing hope that the phase would begin after obtaining the required permits from the ministry.
In the first phase, the jab was given to 135 volunteers, he said, describing their present health condition as favorable.
Karimi noted that the volunteers were between 18 and 55 years old, 41 of whom were female.
He harbored hope that in the second phase, the vaccine will be tested on 500 volunteers.
In addition to Fakhra, Iran is developing three other vaccines which are passing their human trials. The COVID-19 jabs include COVIran Barakat, developed by experts at the Execution of Imam Khomeini’s Order, Razi COV-Pars, developed by the Razi Vaccine and Serum Research Institute, and, finally, Soberana 2, which is the result of the cooperation of Iran’s Pasteur Institute and Cuba’s Finlay Vaccine Institute.
In addition, speaking at the first meeting of Iran’s COVID-19 public vaccination headquarters on Wednesday, Jalil Koohpayeh, the head of Iran University of Medical Sciences, said close to 20 million doses of the jab is required to inoculate Tehran’s population (of about 10 million).